Article Text

other Versions

Download PDFPDF
Vaccine evaluation: lessons from a meningococcal B vaccine
  1. Avishay Sarfatti1,
  2. Federico Martinón-Torres2,
  3. Simon Nadel3
  1. 1Paediatric Intensive Care, Paediatric Intensive Care Unit, St. Mary's Hospital, London, UK
  2. 2Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
  3. 3Paediatric Intensive Care, Paediatric Intensive Care Unit, St. Mary's Hospital and Imperial College London, London, UK
  1. Correspondence to Dr Simon Nadel, Paediatric Intensive Care, Paediatric Intensive Care Unit, St. Mary's Hospital and Imperial College London, Praed Street, London W21NY, UK; nadel{at}

Statistics from

Vaccination is among the most effective public health interventions of the past century, with immunisations against some of the most common and devastating childhood infections already in use to great effect. The development of new vaccines depends on advances in the field of vaccinology that carry high monetary costs. In most countries, these costs pose an obstacle to adoption of new vaccines. To that end, together with the scientific evaluation of new vaccines, an economic evaluation is vital. This aims to determine whether investment in the proposed vaccine is worthwhile.

In this article, we will examine one such case study: the evaluation of a new meningococcal B (MenB) vaccine in the UK by the Joint Committee on Vaccination and Immunization (JCVI). We are well aware of the constraints imposed by a definite health budget; at the same time, we would like to raise awareness to the problems inherent in and the somewhat speculative nature of the economic model when applied to vaccine evaluation. Though some of the aspects of this case are specific to the UK, the principles of this evaluation are relevant to all modern health systems.

In March 2014, JCVI made public its decision to support the introduction of a MenB vaccine (Bexsero) that had been licensed for use in Europe the year before.1 ,2 JCVI recommended that the vaccine should be introduced into the UK routine infant immunisation schedule if the appropriate price per vaccine dose could be negotiated.

This decision is welcome news to the medical profession, to meningitis patients’ advocacy groups, to the population in general and to the vaccine manufacturers. The process by which Bexsero was recommended highlighted the central role that health economics and cost-effectiveness analysis play in such decisions. The difficulties that JCVI faced when reaching its eventual decision suggest …

View Full Text


  • Twitter Follow Avishay Sarfatti at @dfg

  • Contributors All authors contributed to writing and editing the manuscript.

  • Competing interests SN has received an educational grant and acted as a consultant for Novartis Vaccines. FM-T has received funding for research and consultancy from Novartis and manufacturers of other meningococcal vaccine. AS has no competing interests to report.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.